Literature DB >> 31601455

What Are the Costs of Hip Osteoarthritis in the Year Prior to a Total Hip Arthroplasty?

Azeem T Malik1, John H Alexander1, Daniel D Li1, Mengnai Li1, Safdar N Khan1, Thomas J Scharschmidt1.   

Abstract

BACKGROUND: The majority of the cost analysis literature on total hip arthroplasties (THAs) has been focused around the perioperative and postoperative period, with preoperative costs being overlooked.
METHODS: The Humana Administrative Claims database was used to identify Medicare Advantage (MA) and Commercial beneficiaries undergoing elective primary THAs. Preoperative healthcare resource utilization in the year prior to a THA was grouped into the following categories: office visits, X-rays, magnetic resonance imagings, computed tomography scans, intra-articular steroid and hyaluronic acid injections, physical therapy, and pain medications. Total 1-year costs and per-patient average reimbursements for each category have been reported.
RESULTS: Total 1-year preoperative costs amounted to $21,022,883 (average = $512/patient) and $4,481,401 (average = $764/patient) for MA and Commercial beneficiaries, respectively. The largest proportion of total 1-year costs was accounted for by office visits (35% in Commercial; 41% in MA) followed by pain medications (28% in Commercial; 35% in MA). Conservative treatments (steroid injections, hyaluronic acid injections, physical therapy, and pain medications) alone accounted for 40%-44% of the total 1-year costs prior to a THA. A high healthcare utilization within the last 3 months prior to surgery was noted for opioids and steroid injections.
CONCLUSION: On average, $500-$800/patient is spent on hip osteoarthritis-related care in the year prior to a THA. Despite their potential risks, opioids and steroid injections are often utilized in the last 3 months prior to surgery.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  THA; conservative treatment; costs; preoperative; resource utilization; total hip arthroplasty

Year:  2019        PMID: 31601455     DOI: 10.1016/j.arth.2019.09.020

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  4 in total

Review 1.  Viscosupplementation for hip osteoarthritis: Does systematic review of patient-reported outcome measures support use?

Authors:  Alexander J Acuña; Linsen T Samuel; Stacy H Jeong; Ahmed K Emara; Atul F Kamath
Journal:  J Orthop       Date:  2020-03-25

2.  Resuming hip and knee arthroplasty after COVID-19: ethical implications for wellbeing, safety and the economy.

Authors:  Nanne P Kort; Luigi Zagra; Enrique Gomez Barrena; Reha N Tandogan; Martin Thaler; James R Berstock; Theofilos Karachalios
Journal:  Hip Int       Date:  2020-07-07       Impact factor: 2.135

3.  Disruption of joint arthroplasty services in Europe during the COVID-19 pandemic: an online survey within the European Hip Society (EHS) and the European Knee Associates (EKA).

Authors:  M Thaler; Ismail Khosravi; M T Hirschmann; N P Kort; L Zagra; J A Epinette; M C Liebensteiner
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-05-02       Impact factor: 4.342

4.  The long road to recovery: at six months since the first COVID-19 wave, elective orthopedic care has still not fully recovered in Belgium.

Authors:  Y N Tan; P J Vandekerckhove; P Verdonk
Journal:  J Exp Orthop       Date:  2020-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.